



WHO WE ARE

Launched in March 2020, COVID-NMA is an international initiative working in conjunction with the World Health Organization (WHO), led by a team of researchers from Cochrane and other institutions (Université de Paris, Inserm, CNRS, Centre for Evidence-Based Medicine Odense (CEBMO), University of Southern Denmark, Odense University Hospital, Epistemonkos Foundation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan).

This initiative involves a broad multidisciplinary consortium.

OUR VISION

Decisions on COVID-19 treatments and preventive interventions are informed through a living Evidence Ecosystem developed by an international collaborative effort.

OUR MISSIONS

- To inform research planning by producing an up-to-date mapping of trial evidence
- To inform public health and healthcare decisions by producing relevant, accessible, up-to-date, and trustworthy synthesis of high-

- quality evidence about the efficacy and safety of interventions for the prevention or treatment of COVID-19
- To improve research value by producing a living monitoring of trial planning, conduct, and reporting and implementing interventions to transform research practices

OUR GOALS

Our project relies on three main pillars:

- 1. Performing a living mapping of all registered trial evidence to help funders and researchers planning future trials,
- 2. Producing a living systematic review of trial evidence to support healthcare decision making
- 3. Assessing trials methodology and transparency to improve future research.

OUR VALUES AND PRINCIPLES

- Pooling resources and diverse expertise of an international collaboration
- Ensuring flexibility to answer stakeholders' needs
- Ensuring quality, transparency and reproducibility































Legal Notices